Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in enzyme-based solutions for pharmaceutical manufacturing, announced today that it plans to attend the 2026 BIO International Convention, scheduled for June 22–25, 2026, in San Diego, California. The BIO International Convention is a premier global gathering for biotechnology and life sciences companies, academic institutions, and industry participants, covering a wide range of scientific and commercial disciplines.
Representatives of Quantumzyme expect to attend the conference and engage in informal networking meetings with industry participants. The company will not be presenting, exhibiting, sponsoring, or formally participating in conference programming. According to Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., "We view the BIO International Convention as an important opportunity to connect with peers across the biotechnology and biomanufacturing ecosystem. Our attendance is focused on listening, learning, and engaging in informal discussions with industry participants as we continue to evaluate developments relevant to our technology and long-term objectives."
Quantumzyme's attendance is limited to observation and networking activities only, consistent with its ongoing efforts to increase industry awareness and maintain dialogue with potential collaborators, technology partners, and other stakeholders. However, the company noted that there can be no assurance that discussions initiated during the conference will result in any agreements, transactions, or future business relationships.
Additional information regarding the BIO International Convention is available at https://convention.bio.org. For more information and updates, visit the company's website at www.quantumzymecorp.com and its profile at www.otcmarkets.com/stock/QTZM.
Quantumzyme Corp. is a biotransformation company focused on advancing sustainable enzyme-based solutions for pharmaceutical manufacturing. Specializing in green chemistry, the company applies quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts designed to enhance efficiency, reduce waste, and support environmentally responsible production. By integrating computational modeling with laboratory validation, Quantumzyme aims to deliver scalable, cost-effective biocatalysis solutions that improve industrial sustainability.
The information contained in this press release is provided by Quantumzyme Corp. for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice.
